Table 1 mTOR expression profile in pathological settings
From: Expression of mTOR in normal and pathological conditions
Disease/Condition | mTOR Expression Level | Ref. |
|---|---|---|
BRAIN | ||
Alzheimer | β-amyloid increased the expression of mTOR and p-mTOR (at Ser2448) and mTOR translocation to the nucleus | [100] |
Vascular dementia | mTOR and p-mTOR protein levels were decreased at 21- and 28-days after chronic cerebral hypoperfusion (CCH) in the hippocampal CA1 region. | [101] |
LUNG | ||
Idiopathic pulmonary fibrosis | The expression of mTOR correlated with the fibrosis score and lung function decline. | [102] |
SKIN | ||
Dermatitis | mTOR expression was significantly increased in psoriasis, allergic contact dermatitis and atopic dermatitis. | [103] |
Acne | mTOR expression was increased in the skin of acne patients (either in involved or non-involved skin) | [104] |
Pathological scar | Increased mTOR expression in pathological scar fibroblasts. | [105] |
GASTROINTESTINAL TRACT | ||
Diabetic nephropathy | Elevated mTOR mRNA levels | [106] |
Lupus Erythematosus | Increase in mTOR protein levels in liver samples from a murine model of systemic lupus erythematosus, despite a reduction in mRNA levels. | [89] |
BLOOD | ||
Blood | mTOR expression in peripheral blood of patients with osteoarthritic vary from high to low, in which high levels are associated with increased incidence of synovitis. | [107] |
In cord blood cells, the presence of IL2, IL7 and IL15 altogether resulted in an increase of mTOR expression at day 14, and a decrease at day 21. The reduction of mTOR expression was observed when cells were treated with IL2 or IL15 alone but not IL7. | [108] | |